Johns Hopkins Medicine

Alzheimer's Disease Research Center

Abhay Moghekar, M.D.

Abhay Moghekar, M.D.

Clinical Core Co-Leader
Biomarker Core: Co-Leader

Dr. Moghekar's research interests pertain to biomarkers in cerebrospinal fluid (CSF). He is examining standard Alzheimer's disease CSF biomarkers in a range of subject populations and conducting studies to identify novel CSF biomarkers.


  • Sathe G, Na C, Renuse S, Madugundu A, Albert M, Moghekar A, Pandey A. Phosphotyrosine profiling of human cerebrospinal fluid. Clinical Proteomics 2018, 15:29.
  • Sathe G, Na C, Santosh R, Magunundu A, Albert M, Moghekar A, Pandey A. Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer's disease. Proteomics Clinical Applications 2018 [epub ahead of print]
  • Soldan A, Pettigrew C, Cai Q, Wang M-C, Moghekar A, O'Brien R, Albert M. Hypothetical preclinical AD groups and longitudinal cognitive change. JAMA Neurol 2016; 73: 698-705.
  • Resnick S, Bilgel M, Moghekar A, An Y, Cai Q, Wang M-C, Thambisetty M, Prince J, Zhou Y, Soldan A, Wong D, O'Brien R, Ferrucci L, Albert M. Changes in Abeta biomarkers and associations with ApoE genotype in two longitudinal cohorts. Neurobiol Aging 2015; 36: 2333-2339.
  • Semba RD, Moghekar AR, Hu J, Sun L, Turner R, Ferrucci L, O'Brien R. Klotho in the cerebrospinal fluid of adults with and without Alzheimer's disease. Neurosci Lett 2014 558: 37-40.
  • Moghekar A, Li S, Lu Y, Li M, Wang MC, Albert M, O'Brien R. CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology.2013; 81: 1753-1758.


Primary Appointment in Neurology